OR WAIT null SECS
OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that Kos Life Sciences, Inc., a wholly owned subsidiary of Kos Pharmaceuticals, Inc. has selected OmniComm Systems, Inc's TrialMaster Phase I solution to provide electronic data capture (EDC) service and support for a series of up to ten Phase I trials in 2005.
FT. LAUDERDALE, FL -- (MARKET WIRE) -- 06/07/2005 -- OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that Kos Life Sciences, Inc., a wholly owned subsidiary of Kos Pharmaceuticals, Inc. has selected OmniComm Systems, Inc's TrialMaster Phase I solution to provide electronic data capture (EDC) service and support for a series of up to ten Phase I trials in 2005.
Kos will use the TrialMaster Phase I application to collect data at Phase I in-patient units. Laboratory data will be imported into the application allowing normal range verification, the ability to query laboratory data, and reduce or eliminate the need to combine multiple streams of data in order to complete analysis.
"We are currently working with Kos in the Phase IV area. We are delighted that they have decided to utilize our services and products in their Phase I division," said Cornelis Wit, CEO and President of OmniComm Systems, Inc. "Our continued success with TrialMaster in the Phase I area confirms our belief in the flexibility of TrialMaster and the benefits of reasonably priced EDC services to speed the clinical development cycle."
About Kos Pharmaceuticals, Inc.
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, or patient compliance. The Company currently markets Niaspan and Advicor for the treatment of cholesterol disorders, Teveten and TevetenHCT for the treatment of hypertension, CardizemLA for the treatment of hypertension and angina, and Azmacortfor the treatment of asthma. Kos is developing additional products, has proprietary drug delivery technologies in solid-dose and aerosol metered-dose inhalation administration and is pursuing certain strategic business development and licensing opportunities.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. (www.omnicomm.com) is one of the fastest growing companies in the EDC market place targeting its product TrialMaster to the pharmaceutical, medical device and biotechnology companies as well as CRO's. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employee's commitment to on-time, quality and within budget performance.
The TrialMaster (www.trialmaster.com) system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.